Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of Compounds of the general formula (I)

$$R^{2}$$
 R^{3}
 R^{4}
 R^{5}
 R^{6}
 OR^{7}
 OR^{7}
 OR^{1}
 OR^{1}

in which

- R¹ represents phenyl or represents 5- or 6-membered heteroaryl having up to two heteroatoms from the group consisting of N, O and S, which radicals may for their part each be mono- to trisubstituted by identical or different substituents selected from the group consisting of halogen, cyano, nitro, (C₁-C₆)-alkyl (which for its part may be substituted by hydroxyl), (C₁-C₆)-alkoxy, trifluoromethyl, trifluoromethoxy, (C₁-C₆)-alkylsulphonyl, (C₁-C₆)-alkanoyl, (C₁-C₆)-alkoxycarbonyl, carboxyl, amino, (C₁-C₆)-acylamino, mono- and di-(C₁-C₆)-alkylamino,
- R^2 and R^3 are identical or different and independently of one another represent hydrogen or (C_1-C_4) -alkyl or together with the carbon atom to which they are attached form a 3- to 7-membered spiro-linked cycloalkyl ring,
- R^4 represents hydrogen or (C_1-C_4) -alkyl,
- R^5 and R^6 are identical or different and independently of one another represent hydrogen or (C_1-C_4) -alkyl,

R⁷ represents hydrogen or also represents a hydrolyzable group which can be degraded to the corresponding carboxylic acid,

and

n represents the number 1 or 2,

or a pharmaceutically acceptable salt thereof and their pharmaceutically acceptable salts, solvates and solvates of the salts.

- 2. (currently amended) The compound of Compounds of the general formula (I) according to Claim 1 in which
 - R¹ represents phenyl which may be mono- or disubstituted by identical or different substituents selected from the group consisting of fluorine, chlorine, cyano, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy, trifluoromethyl, trifluoromethoxy, methylsulphonyl, acetyl, propionyl, (C₁-C₄)-alkoxycarbonyl, amino, acetylamino, mono- and di-(C₁-C₄)-alkylamino,
 - R^2 and R^3 are identical or different and independently of one another represent hydrogen or (C_1-C_4) -alkyl or together with the carbon atom to which they are attached form a 5- or 6-membered, spiro-linked cycloalkyl ring,
 - R⁴ represents hydrogen or methyl,
 - R⁵ and R⁶ are identical or different and independently of one another represent hydrogen or methyl,
 - R⁷ represents hydrogen,

and

n represents the number 1 or 2.

- 3. (currently amended) The compound of Compounds of the general formula (l) according to Claim 1, in which
 - R¹ represents phenyl which may be mono- or disubstituted by identical or different substituents selected from the group consisting of fluorine, chlorine, methyl, trifluoromethyl and trifluoromethoxy,
 - R² represents methyl,
 - R³ represents methyl,

or

- R² and R³ together with the carbon atom to which they are attached form a spiro-linked cyclopentane or cyclohexane ring,
- R⁴ represents hydrogen or methyl,
- R⁵ and R⁶ each represent hydrogen,
- R⁷ represents hydrogen,

and

n represents the number 1 or 2.

4. (currently amended) A compound of Compounds of the formula (I-A)

$$CH_3$$
 CH_3
 CH_3
 $COOH$
 $COOH$

in which

R¹ represents phenyl which is substituted by fluorine, chlorine or trifluoromethyl, and

- n represents the number 1 or 2.
- 5. (currently amended) A process for preparing a compound of claim 1 or claim 4, comprising initially converting a compound Process for preparing the compounds of the general formula (I) or (I-A) as defined in Claims 1 to 4, characterized in that compounds of the formula (II)

in which R², R³ and R⁴ are each as defined in Claim 1 and

Y represents chlorine or bromine,

are initially converted by methods known from the literature into a compound compounds of the formula (III)

$$PG$$
 R^{2}
 R^{3}
 R^{4}
 PG
(III),

in which Y, R², R³ and R⁴ are each as defined in Claim 1 and

PG represents a suitable amino protective group, preferably 4-nitrophenylsulphonyl,

then reacting this compound these compounds are then reacted in a coupling reaction

with a compound of the formula (IV)

$$R^{1}$$
 B $O-R^{8}$ (IV) ,

in which R¹ is as defined in Claim 1 and

 R^8 represents hydrogen or methyl or both radicals together form a CH_2CH_2 - or $C(CH_3)_2$ - $C(CH_3)_2$ - bridge,

in an inert solvent in the presence of a suitable palladium catalyst and a base, to give <u>a</u> <u>compound</u> <u>compounds</u> of the formula (V)

$$R^{1}$$
 R^{2}
 R^{3}
 R^{4}
 PG
 $(V),$

in which PG, R¹, R², R³ and R⁴ are each as defined in Claim 1,

then removing the protective group PG is then removed using methods known from the literature, to give a compound compounds of the formula (VI)

$$R^1$$
 R^2
 R^3
 R^4
(VI),

in which R¹, R², R³ and R⁴ are each as defined in Claim 1,

 $\underline{\text{then converting the compound}}$ the compounds are then , using a compound of the formula (VII)

$$CI$$
 $O = I$
 $O = I$

in which R5, R6 and n are each as defined in Claim 1 and

T represents benzyl or (C_1-C_6) -alkyl,

in an inert solvent in the presence of a base converted into a compound compounds of the formula (VIII)

in which n, T, R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are each as defined in Claim 1,

then converting the compound the compounds of the formula (VIII) are then with acids or bases or, if T represents benzyl, also hydrogenolytically into the corresponding carboxylic acid acids of the formula (IX)

in which n, R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are each as defined in Claim 1,

<u>further modifying this carboxylic acid</u> these carboxylic acids (IX) are, if appropriate, modified further using known esterification methods to give a compound compounds of the formula (I),

and <u>converting</u> the resulting <u>compound</u> <u>compounds</u> of the formula (IX) or (I) are , if appropriate, <u>converted</u> into <u>their a pharmaceutically acceptable salt thereof</u> <u>solvates</u>, <u>salts and/or solvates of the salts</u> using the corresponding (i) <u>solvents and/or (ii)</u> bases or acids.

- 6. (cancelled)
- 7. (currently amended) A pharmaceutical composition comprising a compound of claim 1
 or 4 Medicaments, comprising at least one compound of the formula (I) or (I-A) as
 defined in Claims 1 to 4 and inert non-toxic pharmaceutically acceptable carriers,
 auxiliaries, solvents, vehicles, emulsifiers and/or dispersants.
- 8. (currently amended) A method for treating or preventing stroke, arteriosclerosis, coronary heart disease or dyslipidaemia, comprising administering to a patient a therapeutically effective amount of a compound of claim 1 or 4 Use of compounds of the formula (I) or (I-A) and medicaments as defined in Claims 1 to 7 for the prophylaxis and treatment of diseases.
- 9. (cancelled)

- 10. (cancelled)
- 11. (cancelled)
- 12. (new) A method for preventing myocardial infection, comprising administering to a patient a therapeutically effective amount of a compound of claim 1 or 4.
- 13. (new) A method for treating restenosis after coronary angioplasty or stenting, comprising administering to a patient a therapeutically effective amount of a compound of claim 1 or 4.